1314972-33-2

Upstream product

• 885592-71-2 (2S,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolane 
• 885592-69-8 (2S,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-one 
• 885592-70-1 (2S,3R,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolan-3-ol 
• 1191237-40-7 C₇H₁₄O₅ 
• 100-44-7 benzyl chloride 
• 1191237-41-8 C₂₈H₃₂O₅ 

Downstream Products

• 885592-73-4 2-(3,4-bis(benzyloxy)-5-(benzyloxymethyl)-3-methyl-tetrahydrofuran-2-yl)acetonitrile 
• 1185740-47-9 C₃₁H₃₅NO₅ 
• 1192264-50-8 C₃₁H₃₆O₆ 
• 917567-08-9 (3R,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxolan-2-one 
• 1219705-15-3 C₂₉H₃₂O₆ 
• 1191237-48-5 C₃₄H₃₃N₅O₄ 
• 1350736-07-0 C₁₃H₁₅N₅O₄ 
• 1191237-49-6 1′-cyano-2′-C-methyl-4-aza-7,9-dideazaadenosine 
• 1350735-57-7 (2S)-isopropyl 2-((((2R,3R,4R,5R)-5-(4-aminopyrrolo[1,2-f]-[1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1350735-68-0 (2S)-isopropyl 2-((((2R,3R,4R,5R)-3-isobutyroxy-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1350735-69-1 C₂₉H₃₇N₆O₉P 
• 1350735-70-4 [(Sp)-isopropyl 2-((S)-(((2R,3R,4R,5R)-3-isobutyroxy-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy) (phenoxy)phosphorylamino)propanoate] 
• 1191238-04-6 C₃₃H₃₅N₅O₅ 
• 1040273-60-6 7-((2S,3S,4R,5R)-3,4-bis-(benzyloxy)-5-benzyloxymethyl-3-methyl-tetrahydrofuran-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine 

Relevant academic research and scientific papers

Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides

Synthetic nucleoside analogues characterized by a C–C anomeric linkage form a family of promising therapeutics against infectious and malignant diseases. Herein, C-nucleosides comprising structural variations at the sugar and nucleobase moieties were exam

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS

Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.

1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT

Provided are prodrugs of pyrrolo[l,2-f][l,2,4]triazin-7-yl nucleoside phosphates wherein the 1 '' position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections.

CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Provided are thieno[3,4-d]pyrimidin-7-yI and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Provided are imidazol [1,5-f] [1,2.4]triazinyl, imidazol [1,2,4]triazinyl, and [1,2,4] triazolo [4,3-f] [1,2,4] triazinyl nucleosides of formula I nucleoside phosphates and prodrugs thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. Wherein X1 or X2 is indepently C-R10 or N and wherein at least one of X1 or X2 is N.

THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES

The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.